Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: A study of the Fondazione Italiana Linfomi

Luca Arcaini, D. Vallisa, S. Rattotti, V. V. Ferretti, A. J M Ferreri, P. Bernuzzi, M. Merli, M. Varettoni, A. Chiappella, A. Ambrosetti, A. Tucci, C. Rusconi, C. Visco, M. Spina, G. Cabras, S. Luminari, M. Tucci, P. Musto, M. Ladetto, F. MerliC. Stelitano, A. d'Arco, L. Rigacci, A. Levis, D. Rossi, P. Spedini, S. Mancuso, D. Marino, R. Bruno, L. Baldini, A. Pulsoni

Research output: Contribution to journalArticle

Abstract

Background: Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). Patients and methods: We carried out a cohort study of 704 consecutive HIV-negative, HCV-positive patients with indolent NHL diagnosed and treated from 1993 to 2009 in 39 centers of the Fondazione Italiana Linfomi; 134 patients were managed with AT for lymphoma control. Results: For entire cohort, 5-year overall survival (OS) was 78% [95% confidence interval (CI): 74%-82%] and 5-year progression-free survival (PFS) was 48% (95% CI: 44%-53%). In multivariate analysis, the use of AT during the patients' life had positive impact on OS. Forty-four of the 100 patients treated with first-line AT achieved a complete remission (CR) and 33 a partial response (PR). HCV-RNA clearance was achieved in 80 patients and was related to lymphoma response. At a median follow-up of 3.6 years, 5-year PFS was 63% (95% CI: 50%-73%). CR + PR rate was 85% with AT as second-line treatment. Conclusion: AT produces HCV-RNA clearance and consequent tumor regression in most patients with HCV-related indolent NHL. AT used at any time is associated with improved OS. Consequently, AT can be considered an option for patients with indolent lymphomas who do not need immediate cytoreductive treatment.

Original languageEnglish
Article numbermdu166
Pages (from-to)1404-1410
Number of pages7
JournalAnnals of Oncology
Volume25
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

B-Cell Lymphoma
Virus Diseases
Hepacivirus
Antiviral Agents
Therapeutics
Lymphoma
Confidence Intervals
Disease-Free Survival
Survival
RNA
Non-Hodgkin's Lymphoma
Neoplasms
Cohort Studies
Multivariate Analysis
HIV

Keywords

  • Antiviral treatment
  • HCV
  • Indolent lymphoma
  • Outcome

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection : A study of the Fondazione Italiana Linfomi. / Arcaini, Luca; Vallisa, D.; Rattotti, S.; Ferretti, V. V.; Ferreri, A. J M; Bernuzzi, P.; Merli, M.; Varettoni, M.; Chiappella, A.; Ambrosetti, A.; Tucci, A.; Rusconi, C.; Visco, C.; Spina, M.; Cabras, G.; Luminari, S.; Tucci, M.; Musto, P.; Ladetto, M.; Merli, F.; Stelitano, C.; d'Arco, A.; Rigacci, L.; Levis, A.; Rossi, D.; Spedini, P.; Mancuso, S.; Marino, D.; Bruno, R.; Baldini, L.; Pulsoni, A.

In: Annals of Oncology, Vol. 25, No. 7, mdu166, 2014, p. 1404-1410.

Research output: Contribution to journalArticle

Arcaini, L, Vallisa, D, Rattotti, S, Ferretti, VV, Ferreri, AJM, Bernuzzi, P, Merli, M, Varettoni, M, Chiappella, A, Ambrosetti, A, Tucci, A, Rusconi, C, Visco, C, Spina, M, Cabras, G, Luminari, S, Tucci, M, Musto, P, Ladetto, M, Merli, F, Stelitano, C, d'Arco, A, Rigacci, L, Levis, A, Rossi, D, Spedini, P, Mancuso, S, Marino, D, Bruno, R, Baldini, L & Pulsoni, A 2014, 'Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: A study of the Fondazione Italiana Linfomi', Annals of Oncology, vol. 25, no. 7, mdu166, pp. 1404-1410. https://doi.org/10.1093/annonc/mdu166
Arcaini, Luca ; Vallisa, D. ; Rattotti, S. ; Ferretti, V. V. ; Ferreri, A. J M ; Bernuzzi, P. ; Merli, M. ; Varettoni, M. ; Chiappella, A. ; Ambrosetti, A. ; Tucci, A. ; Rusconi, C. ; Visco, C. ; Spina, M. ; Cabras, G. ; Luminari, S. ; Tucci, M. ; Musto, P. ; Ladetto, M. ; Merli, F. ; Stelitano, C. ; d'Arco, A. ; Rigacci, L. ; Levis, A. ; Rossi, D. ; Spedini, P. ; Mancuso, S. ; Marino, D. ; Bruno, R. ; Baldini, L. ; Pulsoni, A. / Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection : A study of the Fondazione Italiana Linfomi. In: Annals of Oncology. 2014 ; Vol. 25, No. 7. pp. 1404-1410.
@article{e77c7f572938450aaca7f3ee1c5036d7,
title = "Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: A study of the Fondazione Italiana Linfomi",
abstract = "Background: Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). Patients and methods: We carried out a cohort study of 704 consecutive HIV-negative, HCV-positive patients with indolent NHL diagnosed and treated from 1993 to 2009 in 39 centers of the Fondazione Italiana Linfomi; 134 patients were managed with AT for lymphoma control. Results: For entire cohort, 5-year overall survival (OS) was 78{\%} [95{\%} confidence interval (CI): 74{\%}-82{\%}] and 5-year progression-free survival (PFS) was 48{\%} (95{\%} CI: 44{\%}-53{\%}). In multivariate analysis, the use of AT during the patients' life had positive impact on OS. Forty-four of the 100 patients treated with first-line AT achieved a complete remission (CR) and 33 a partial response (PR). HCV-RNA clearance was achieved in 80 patients and was related to lymphoma response. At a median follow-up of 3.6 years, 5-year PFS was 63{\%} (95{\%} CI: 50{\%}-73{\%}). CR + PR rate was 85{\%} with AT as second-line treatment. Conclusion: AT produces HCV-RNA clearance and consequent tumor regression in most patients with HCV-related indolent NHL. AT used at any time is associated with improved OS. Consequently, AT can be considered an option for patients with indolent lymphomas who do not need immediate cytoreductive treatment.",
keywords = "Antiviral treatment, HCV, Indolent lymphoma, Outcome",
author = "Luca Arcaini and D. Vallisa and S. Rattotti and Ferretti, {V. V.} and Ferreri, {A. J M} and P. Bernuzzi and M. Merli and M. Varettoni and A. Chiappella and A. Ambrosetti and A. Tucci and C. Rusconi and C. Visco and M. Spina and G. Cabras and S. Luminari and M. Tucci and P. Musto and M. Ladetto and F. Merli and C. Stelitano and A. d'Arco and L. Rigacci and A. Levis and D. Rossi and P. Spedini and S. Mancuso and D. Marino and R. Bruno and L. Baldini and A. Pulsoni",
year = "2014",
doi = "10.1093/annonc/mdu166",
language = "English",
volume = "25",
pages = "1404--1410",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection

T2 - A study of the Fondazione Italiana Linfomi

AU - Arcaini, Luca

AU - Vallisa, D.

AU - Rattotti, S.

AU - Ferretti, V. V.

AU - Ferreri, A. J M

AU - Bernuzzi, P.

AU - Merli, M.

AU - Varettoni, M.

AU - Chiappella, A.

AU - Ambrosetti, A.

AU - Tucci, A.

AU - Rusconi, C.

AU - Visco, C.

AU - Spina, M.

AU - Cabras, G.

AU - Luminari, S.

AU - Tucci, M.

AU - Musto, P.

AU - Ladetto, M.

AU - Merli, F.

AU - Stelitano, C.

AU - d'Arco, A.

AU - Rigacci, L.

AU - Levis, A.

AU - Rossi, D.

AU - Spedini, P.

AU - Mancuso, S.

AU - Marino, D.

AU - Bruno, R.

AU - Baldini, L.

AU - Pulsoni, A.

PY - 2014

Y1 - 2014

N2 - Background: Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). Patients and methods: We carried out a cohort study of 704 consecutive HIV-negative, HCV-positive patients with indolent NHL diagnosed and treated from 1993 to 2009 in 39 centers of the Fondazione Italiana Linfomi; 134 patients were managed with AT for lymphoma control. Results: For entire cohort, 5-year overall survival (OS) was 78% [95% confidence interval (CI): 74%-82%] and 5-year progression-free survival (PFS) was 48% (95% CI: 44%-53%). In multivariate analysis, the use of AT during the patients' life had positive impact on OS. Forty-four of the 100 patients treated with first-line AT achieved a complete remission (CR) and 33 a partial response (PR). HCV-RNA clearance was achieved in 80 patients and was related to lymphoma response. At a median follow-up of 3.6 years, 5-year PFS was 63% (95% CI: 50%-73%). CR + PR rate was 85% with AT as second-line treatment. Conclusion: AT produces HCV-RNA clearance and consequent tumor regression in most patients with HCV-related indolent NHL. AT used at any time is associated with improved OS. Consequently, AT can be considered an option for patients with indolent lymphomas who do not need immediate cytoreductive treatment.

AB - Background: Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). Patients and methods: We carried out a cohort study of 704 consecutive HIV-negative, HCV-positive patients with indolent NHL diagnosed and treated from 1993 to 2009 in 39 centers of the Fondazione Italiana Linfomi; 134 patients were managed with AT for lymphoma control. Results: For entire cohort, 5-year overall survival (OS) was 78% [95% confidence interval (CI): 74%-82%] and 5-year progression-free survival (PFS) was 48% (95% CI: 44%-53%). In multivariate analysis, the use of AT during the patients' life had positive impact on OS. Forty-four of the 100 patients treated with first-line AT achieved a complete remission (CR) and 33 a partial response (PR). HCV-RNA clearance was achieved in 80 patients and was related to lymphoma response. At a median follow-up of 3.6 years, 5-year PFS was 63% (95% CI: 50%-73%). CR + PR rate was 85% with AT as second-line treatment. Conclusion: AT produces HCV-RNA clearance and consequent tumor regression in most patients with HCV-related indolent NHL. AT used at any time is associated with improved OS. Consequently, AT can be considered an option for patients with indolent lymphomas who do not need immediate cytoreductive treatment.

KW - Antiviral treatment

KW - HCV

KW - Indolent lymphoma

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=84903701048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903701048&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu166

DO - 10.1093/annonc/mdu166

M3 - Article

C2 - 24799461

AN - SCOPUS:84903701048

VL - 25

SP - 1404

EP - 1410

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

M1 - mdu166

ER -